The combination of targeted therapy with immune checkpoint inhibition (ICI) is an area of
intense interest. We studied the interaction of fibroblast growth factor receptor (FGFR) …

In this review, we revisit the pivotal role of fibroblast growth factor receptor 3 (FGFR3) in
bladder cancer (BLCA), underscoring its prevalence in both non‐muscle‐invasive and …

Background Genomic regions identified by genome-wide association studies (GWAS) for
bladder cancer risk provide new insights into etiology. Objective To identify new …

Background Molecular understanding of muscle-invasive (MIBC) and non–muscle-invasive
(NMIBC) bladder cancer is currently based primarily on transcriptomic and genomic …

Urothelial cancer of the urinary bladder frequently metastasizes to lymph‐nodes, lungs, liver
and bone. A taxonomy for molecular classification exists, but it is unknown if molecular …

Abstract Purpose of Review This review summarizes the druggable targets within the critical
signaling pathways and the promising clinically relevant drugs emerging as potential …

Background The role of Eph receptors and related ephrin (EFN) ligands (as the largest
family of transmembrane-bound RTKs) in immunomodulation in many types of cancer …

Objective KDM6A, a representative tumour suppressor gene with sex bias, is frequently
altered in urothelial carcinoma (UC). The specific impacts of KDM6A mutations on gender …

膀胱癌(bladder cancer, BCa) 是泌尿系统常见的恶性肿瘤之一. 目前对于BCa
的基础和临床研究均取得了重要进展, 在基因和蛋白质层面进一步阐释了BCa 发生 …

Background The effective management of bladder cancer (BCa) depends on the early
diagnosis and surveillance. Previous studies have explored numerous urinary molecules as …